TY - JOUR. T1 - Validating genetic risk associations for ovarian cancer through the international Ovarian Cancer Association Consortium. AU - Pearce, C. L.. AU - Near, A. M.. AU - Van Den Berg, D. J.. AU - Ramus, S. J.. AU - Gentry-Maharaj, A.. AU - Menon, U.. AU - Gayther, S. A.. AU - Anderson, A. R.. AU - Edlund, C. K.. AU - Wu, A. H.. AU - Chen, X.. AU - Beesley, J.. AU - Webb, P. M.. AU - Holt, S. K.. AU - Chen, C.. AU - Doherty, J. A.. AU - Rossing, M. A.. AU - Whittemore, A. S.. AU - McGuire, V.. AU - DiCioccio, R. A.. AU - Goodman, M. T.. AU - Lurie, G.. AU - Carney, M. E.. AU - Wilkens, L. R.. AU - Ness, R. B.. AU - Moysich, K. B.. AU - Edwards, R.. AU - Jennison, E.. AU - Kjaer, S. K.. AU - Hogdall, E.. AU - Hogdall, C. K.. AU - Goode, E. L.. AU - Sellers, T. A.. AU - Vierkant, R. A.. AU - Cunningham, J. C.. AU - Schildkraut, J. M.. AU - Berchuck, A.. AU - Moorman, P. G.. AU - Iversen, E. S.. AU - Cramer, D. W.. AU - Terry, K. L.. AU - Vitonis, A. F.. AU - Titus-Ernstoff, L.. AU - Song, ...
Modulation of epithelial neoplasia and lymphoid hyperplasia in PTEN +/- mice by the p85 regulatory subunits of phosphoinositide 3-kinase Academic Article ...
Treatment of EOC in a curative setting demonstrated to require high doses of radiation. However, most patients diagnosed with EOC often present with disseminated disease involving the abdominal cavity and prescription of adequately high doses of radiation for the eradication of any bulky disease was difficult without inducing high rates of toxicity [20,27]. The current NCCN guideline for ovarian cancer recommends RT only in the palliative setting, where most references are from the early 2000s and data based on the use of modern-day RT techniques is difficult to find [11]. Because the role of RT has been nearly nonexistent after the growth of platinum-based chemotherapy, majority of data on historical WAI are based on 2D techniques of RT. According to the few studies that has been published in more recent years, the response rate after RT has been noted to be relatively high. In a study by Tinger et al. [1] on palliative RT for symptomatic lesions in 80 patients diagnosed with EOC, the overall ...
PRIMARY OBJECTIVES I. Objective tumour response rate (complete plus partial response as defined by the RECIST criteria) in women with recurrent or refractory advanced ovarian or primary peritoneal cancer.. SECONDARY OBJECTIVES:. I. Median survival time. II. 6-month survival rate. III. Objective tumour stable disease rate. IV. Response duration. V. Toxicity. VI. Time to disease progression.. OUTLINE: This is a multicenter study.. Course 1 (56 days): Patients receive oral sorafenib twice daily on days 1-56 and gemcitabine IV over 30 minutes on days 1, 8, 15, 22, 29, 36, and 43.. Course 2 and all subsequent courses (28 days): Patients receive oral sorafenib twice daily on days 1-28 and gemcitabine IV over 30 minutes on days 1, 8, and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.. Patients with a complete or partial response receive at least 2 additional courses beyond documented response. Patients with stable or responding disease who have received ...
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining two or more drugs may
I. Ray-Coquard (1), C. Le Tourneau (2), N. Isambert (3), C. A. Gomez-Roca (4), P. Cassier (1), M. P. Sablin (2), D. Purcea (5), E. Rouits (5), C. Schu...
Human epithelial cancer cells (HeLa) stained for microtubules (green), kinetochores (pink/red) and DNA (blue). Two metaphase cells can be seen on the left, and a telophase cell is on the bottom. The remaining cells are in interphase. - Stock Image M133/0153
OBJECTIVES: We evaluated in a large study meta-database of prospectively randomised phase III trials the prognostic factors for progression-free survival (PFS) and overall survival (OS) in patients , and ,40 years of age with advanced epithelial ovarian cancer. METHODS: A total of 5055 patients of the AGO, GINECO, NSGO intergroup studies AGO-OVAR 3, 5, 7 and 9 were merged to identify 294 patients ,40 years and 4761 patients ≥40 years. We conducted survival analyses and Cox proportional hazard regression models and additionally analysed a very homogeneous subcohort of 405 patients with serous epithelial ovarian cancer, excellent performance status, who had received complete macroscopic upfront cytoreduction and ≥5 chemotherapy cycles ...
OUTLINE: This is a multicenter study.. Patients receive bryostatin 1 IV over 24 hours. Treatment repeats weekly for 8 courses in the absence of disease progression or unacceptable toxicity. Patients achieving stable or regressive disease may receive additional treatment.. Patients are followed for at least 4 weeks after treatment, then every 3 months.. PROJECTED ACCRUAL: A total of 14-25 patients will be accrued for this study. ...
Identifying quantitative image feature based clinical markers that correlate well with the patients clinical outcome is important to establish an optimal personalized cancer treatment strategy and/or develop precision medicine in the future. For this purpose, many studies have been performed by a number of research groups including our group to explore, identify and compute different image feature analysis based clinical markers [13-18]. This study is different from the previous studies in this field (e.g., Radiomics). We demonstrated that the image features computed from non-tumor regions could also provide important and/or supplemental information to assist predicting response of cancer patients to the chemotherapy. Although this study only predicted whether the EOC patients can benefit from receiving the bevacizumab-based chemotherapy, the new computer-aided image processing scheme provides a new quantitative image marker that is also applicable to analyze PFS or OS of EOC patients without ...
PAX8 is a lineage-restricted transcription factor expressed in a large proportion of epithelial ovarian cancers (EOCs). PAX8 is commonly upregulated in EOCs relative to precursor tissues, suggesting it functions as an oncogene. However, the biological role of PAX8 during cancer initiation and development is poorly understood, and the genome-wide transcriptional targets have yet to be comprehensively catalogued. Using stable models of PAX8 knockdown in HEYA8 and IGROV1 EOC cell lines we show that PAX8 knockdown reduces cell proliferation in vitro and tumor growth in vivo. To understand how PAX8 regulates neoplastic phenotypes in cancer cells we performed RNA expression profiling by microarray in HEYA8 and IGROV1 before and after PAX8 knockdown. We also performed chromatin immunoprecipitation followed by next generation sequencing (ChIP-seq) for PAX8 and a marker of active chromatin (H3K27ac) in both cell lines. De novo motif discovery in the ChIP-seq profiles identified a PAX-like binding motif ...
Johnatty, S. E., Beesley, J., Chen, X., Macgregor, S., Duffy, D. L., Spurdle, A. B., deFazio, A., Gava, N., Webb, P. M., Rossing, M. A., Doherty, J. A., Goodman, M. T., Lurie, G., Thompson, P. J., Wilkens, L. R., Ness, R. B., Moysich, K. B., Chang-Claude, J., Wang-Gohrke, S., Cramer, D. W., Terry, K. L., Hankinson, S. E., Tworoger, S. S., Garcia-Closas, M., Yang, H., Lissowska, J., Chanock, S. J., Pharoah, P. D., Song, H., Whitemore, A. S., Pearce, C. L., Stram, D. O., Wu, A. H., Pike, M. C., Gayther, S. A., Ramus, S. J., Menon, U., Gentry-Maharaj, A., Anton-Culver, H., Ziogas, A., Hogdall, E., Kjaer, S. K., Hogdall, C., Berchuck, A., Schildkraut, J. M., Iversen, E. S., Moorman, P. G., Phelan, C. M., Sellers, T. A., Cunningham, J. M. & Ovarian Cancer Association Consortium, 1 jul. 2010, I : P L o S Genetics. 6, 7, s. e1001016. Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › peer review ...
Laboratory of Proteoglycan Signaling and Therapeutics, Faculty of Advanced Life Science, Hokkaido University, Frontier Research Center for Post-Genomic Science and Technology ...
TY - JOUR. T1 - Polymorphisms in stromal genes and susceptibility to serous epithelial ovarian cancer. T2 - A report from the ovarian cancer association consortium. AU - Amankwah, Ernest K.. AU - Wang, Qinggang. AU - Schildkraut, Joellen M.. AU - Tsai, Ya Yu. AU - Ramus, Susan J.. AU - Fridley, Brooke L.. AU - Beesley, Jonathan. AU - Johnatty, Sharon E.. AU - Webb, Penelope M.. AU - Chenevix-Trench, Georgia. AU - Australian Ovarian Cancer Study Group, Ovarian Cancer Study Group. AU - Dale, Laura C.. AU - Lambrechts, Diether. AU - Amant, Frederic. AU - Despierre, Evelyn. AU - Vergote, Ignace. AU - Gayther, Simon A.. AU - Gentry-Maharaj, Aleksandra. AU - Menon, Usha. AU - Chang-Claude, Jenny. AU - Wang-Gohrke, Shan. AU - Anton-Culver, Hoda. AU - Ziogas, Argyrios. AU - Dörk, Thilo. AU - Dürst, Matthias. AU - Antonenkova, Natalia. AU - Bogdanova, Natalia. AU - Brown, Robert. AU - Flanagan, James M.. AU - Kaye, Stanley B.. AU - Paul, James. AU - Bützow, Ralf. AU - Nevanlinna, Heli. AU - Campbell, ...
TY - JOUR. T1 - Role of CSF-1 in progression of epithelial ovarian cancer. AU - Chambers, Setsuko K. PY - 2009. Y1 - 2009. N2 - Despite the dismal outcome seen in the majority of epithelial ovarian cancer patients, there is ongoing progress in understanding the disease at a molecular level. Elucidation of pathways underlying disease progression and metastasis of ovarian cancer is key to development of targeted therapeutics. It is only in this way that therapeutic potential can be translated to reality. Here, we describe the evidence to date for the role of CSF-1/c-fms signaling in ovarian cancer invasiveness and metastasis, including the recent understanding of how CSF-1/c-fms expression is regulated with identification of significant post-transcriptional regulators.. AB - Despite the dismal outcome seen in the majority of epithelial ovarian cancer patients, there is ongoing progress in understanding the disease at a molecular level. Elucidation of pathways underlying disease progression and ...
Additional file 8: of Macrophages derived exosomes deliver miR-223 to epithelial ovarian cancer cells to elicit a chemoresistant phenotype
Dichloroacetate Induces Apoptosis of Epithelial Ovarian Cancer Cells Through a Mechanism Involving Modulation of Oxidative Stress
Response to microtubule-interacting agents in primary epithelial ovarian cancer cells. . Biblioteca virtual para leer y descargar libros, documentos, trabajos y tesis universitarias en PDF. Material universiario, documentación y tareas realizadas por universitarios en nuestra biblioteca. Para descargar gratis y para leer online.
Epithelial ovarian cancer (EOC) is highly lethal gynecological cancer. Forkhead Box Protein C2 (FOXC2) promotes occurrence and development of various malignant tumors. The present study is aimed at exploring the correlation between the polymorphism of FOXC2 and epithelial ovarian cancer susceptibility in Chinese Han population. A case-control design was used to verify the association between FOXC2 polymorphisms and epithelial ovarian cancer. The genotyping was performed using Taqman® SNP Genotyping kit by qRT-PCR. The genetic variants including rs3751794 C | T, rs1035550 A | G, rs4843163 C | G and rs4843396 C | T in FOXC2 gene were analyzed. The strength of the associations was detected using odds ratios and 95% confidence intervals. Stratification analyses showed the association between the FOXC2 gene polymorphisms rs3751794 C | T, rs4843163 C | G and rs4843396 C | T with epithelial ovarian cancer susceptibility in terms of age, metastasis status, clinical stage, pathological grade, pregnant times,
Cell lines and culture. The derivation, source, and propagation of human epithelial ovarian cancer cell lines, such as cisplatin-sensitive (A2780-PAR) and platinum-resistant (A2780-CP20 and RMG2) epithelial ovarian cancer cell lines, were maintained as previously described (30). The A2780-CP20 cell line was developed by sequential exposure of the A2780 cell line to increasing concentrations of cisplatin. All experiments were done with 70% to 80% confluent cultures.. ATP7A and ATP7B gene silencing by siRNA. siRNA constructs targeted to ATP7A and ATP7B were designed and purchased from Qiagen. The target sequences were 5′-CTGGACCGGATTGTTAATTAT-3′ (for ATP7A) and 5′-CCAATTGATATTGAGCGGTTA-3′ (for ATP7B). In vitro transient transfection was done as described previously (28). Briefly, cells were transfected with ATP7A- and/or ATP7B-specific or scrambled (control) siRNA using RNAiFect reagent (Qiagen). At selected time intervals, cells were harvested to measure mRNA and protein levels of ATP7B ...
Previously developed models for predicting absolute risk of invasive epithelial ovarian cancer have included a limited number of risk factors and have had low discriminatory power (area under the receiver operating characteristic curve (AUC) , 0.60). Because of this, we developed and internally validated a relative risk prediction model that incorporates 17 established epidemiologic risk factors and 17 genome-wide significant single nucleotide polymorphisms (SNPs) using data from 11 case-control studies in the United States (5,793 cases; 9,512 controls) from the Ovarian Cancer Association Consortium (data accrued from 1992 to 2010). We developed a hierarchical logistic regression model for predicting case-control status that included imputation of missing data. We randomly divided the data into an 80% training sample and used the remaining 20% for model evaluation. The AUC for the full model was 0.664. A reduced model without SNPs performed similarly (AUC = 0.649). Both models performed better ...
Drug resistance is still one of the key causes of death in epithelial ovarian carcinoma (EOC) patients, however there are very few strategies to reverse chemoresistance. Here we try to clarify whether and how miR-9 takes part in the regulation of paclitaxel sensitivity. miR-9 expressions in EOC cells and tissues were detected by Realtime PCR. The target of miR-9 was validated through dual luciferase reporter assay and Western Blot. Methylation study, RNAi technique and cytotoxicity assay were used to determine the intrinsic mechanism of miR-9 in paclitaxel sensitivity regulation. miR-9 is down-regulated in paclitaxel resistant EOC. The patients with lower miR-9, Grade 3, Stage III -IV and suboptimal surgery present shorter survival time. miR-9 and suboptimal surgery are independent prognostic factors of EOC. Modulating miR-9 expression could change paclitaxel sensitivity of EOC cells. CCNG1, validated as a direct target of miR-9, mediates paclitaxel resistance. miR-9-1 and 3 gene hypermethylation would
Drug resistance is still one of the key causes of death in epithelial ovarian carcinoma (EOC) patients, however there are very few strategies to reverse chemoresistance. Here we try to clarify whether and how miR-9 takes part in the regulation of paclitaxel sensitivity. miR-9 expressions in EOC cells and tissues were detected by Realtime PCR. The target of miR-9 was validated through dual luciferase reporter assay and Western Blot. Methylation study, RNAi technique and cytotoxicity assay were used to determine the intrinsic mechanism of miR-9 in paclitaxel sensitivity regulation. miR-9 is down-regulated in paclitaxel resistant EOC. The patients with lower miR-9, Grade 3, Stage III -IV and suboptimal surgery present shorter survival time. miR-9 and suboptimal surgery are independent prognostic factors of EOC. Modulating miR-9 expression could change paclitaxel sensitivity of EOC cells. CCNG1, validated as a direct target of miR-9, mediates paclitaxel resistance. miR-9-1 and 3 gene hypermethylation would
SYF2 is reported to be as a cell cycle regulator at the G1/S transition and encodes a nuclear protein that interacts with cyclin-D-type binding protein 1. In ou
While some ovarian cancers arise in women with inherited mutations in the BRCA1 or BRCA2 genes, the genetic changes responsible for most ovarian cancers…
臺大位居世界頂尖大學之列,為永久珍藏及向國際展現本校豐碩的研究成果及學術能量,圖書館整合機構典藏(NTUR)與學術庫(AH)不同功能平台,成為臺大學術典藏NTU scholars。期能整合研究能量、促進交流合作、保存學術產出、推廣研究成果。. To permanently archive and promote researcher profiles and scholarly works, Library integrates the services of "NTU Repository" with "Academic Hub" to form NTU Scholars.. ...
Survivin, an anti-apoptosis gene that is abnormally overexpressed in a variety of human tumors, may play an important role in the carcinogenesis and drug resistance of cancer. This study was designed to explore the effects of liposome-survivin antisense oligonucleotide (Lip-ASODN) on the growth and apoptosis of human ovarian cancer cell lines, A2780 and SKOV3. To investigate the use of survivin as a therapeutic target on ovarian cancer, we carried out transfections with Lip-ASODN to induce apoptosis in ovarian cancer cell lines, A2780 and SKOV3. The expression of survivin mRNA and relative protein were evaluated separately by quantitative real-time RT-PCR and Western blot analysis. Cell proliferation inhibition was determined by methyl thiazolyl tetrazolium (MTT) assay, and the induced cell apoptosis was examined using flow cytometry (FCM) after Lip-ASODN transfection. Our results showed that the overexpression of survivin led to infinite carcino-proliferation, and survivin expression in the ...
Sulforaphane (SFN), an isothiocyanate phytochemical present predominantly in cruciferous vegetables such as brussels sprout and broccoli, is considered a promising chemo-preventive agent against cancer. In-vitro exposure to SFN appears to result in the induction of apoptosis and cell-cycle arrest in a variety of tumor types. However, the molecular mechanisms leading to the inhibition of cell cycle progression by SFN are poorly understood in epithelial ovarian cancer cells (EOC). The aim of this study is to understand the signaling mechanisms through which SFN influences the cell growth and proliferation in EOC. SFN at concentrations of 5 - 20 μM induced a dose-dependent suppression of growth in cell lines MDAH 2774 and SkOV-3 with an IC50 of ~8 μM after a 3 day exposure. Combination treatment with chemotherapeutic agent, paclitaxel, resulted in additive growth suppression. SFN at ~8 μM decreased growth by 40% and 20% on day 1 in MDAH 2774 and SkOV-3, respectively. Cells treated with cytotoxic
Cigarette smoking is associated with an increased risk of developing mucinous ovarian tumors but whether it is associated with ovarian cancer survival overall or for the different histotypes is unestablished. Furthermore, it is unknown whether the association between cigarette smoking and survival differs according to strata of ovarian cancer stage at diagnosis. In a large pooled analysis, we evaluated the association between various measures of cigarette smoking and survival among women with epithelial ovarian cancer. We obtained data from 19 case-control studies in the Ovarian Cancer Association Consortium (OCAC), including 9,114 women diagnosed with ovarian cancer. Cox regression models were used to estimate adjusted study-specific hazard ratios (HRs), which were combined into pooled hazard ratios (pHR) with corresponding 95% confidence intervals (CIs) under random effects models. Overall, 5,149 (57%) women died during a median follow-up period of 7.0 years. Among women diagnosed with ovarian cancer,
[40 Pages Report] Check for Discount on Epithelial Ovarian Cancer - Epidemiology Insights to 2025 report by Delve Insight. DelveInsight Epithelial Ovarian Cancer - Epidemiology Forecast To 2025 provides an...
Ovarian cancer is the leading cause of death from gynecological malignancies and the fifth major cancer in women in the world. Once diagnosed, ovarian cancer is usually treated by cytoreductive surgery followed by platinum and taxane-based chemotherapeutic drugs. However, resistance to chemotherapy is a major impediment in management of serous epithelial ovarian cancer (SEOC). We hypothesize that a multifaceted view of the alterations taking place at multiple cellular levels using molecular profiling technologies will offer insight into the mechanisms which play key roles in drug resistant ovarian carcinomas. Also, the application of appropriate bioinformatic and statistical data processing and analysis is of utmost importance in identification of key drug resistance pathways. Current study is performed on 25 high-grade serous epithelial ovarian tumor tissue samples from patients that demonstrated favorable, or unfavorable response to chemotherapy treatment. Four different microarray platforms ...
PubMed comprises more than 30 million citations for biomedical literature from MEDLINE, life science journals, and online books. Citations may include links to full-text content from PubMed Central and publisher web sites.
Serous epithelial ovarian cancer (SEOC) is the most lethal gynecological cancer in the United States with disease recurrence being the major cause of morbidity and mortality. Despite recent advances in our understanding of the molecular mechanisms responsible for the development of SEOC, the survival rate for women with this disease has remained relatively unchanged in the last two decades. Preclinical mouse models of ovarian cancer, including xenograft, syngeneic, and genetically engineered mice, have been developed to provide a mechanism for studying the development and progression of SEOC. Such models strive to increase our understanding of the etiology and dissemination of ovarian cancer in order to overcome barriers to early detection and resistance to standard chemotherapy. Although there is not a single model that is most suitable for studying ovarian cancer, improvements have led to current models that more closely mimic human disease in their genotype and phenotype. Other advances in the field,
RATIONALE: Drugs used in chemotherapy, such as elesclomol sodium and paclitaxel, work in different ways to stop the growth of tumor cells, either by kil
For many years Western gastrointestinal pathologists have followed the recommendations of British gastrointestinal pathologists. We learned that terms such as carcinoma in situ should be banned from the diagnostic terminology as it could lead to misinterpretation by surgeons and to unnecessary surgical intervention.. The Vienna classification1 has introduced new avenues to the understanding of the process of carcinogenesis in the gastrointestinal tract. For some Western pathologists in the Vienna group who also received histopathological training in Japan, the concept of intraepithelial carcinoma (that is, carcinoma in situ) and of intramucosal carcinoma appeared natural. Although during the first day of discussions other Western pathologists appeared reluctant to accept such controversial notions, the discussion became less intense during the second day, and at the end a consensus was reached, gaining finally the pages of this journal.1. The Vienna classification1 dismembered the concept of ...
Ovarian cancer is the most lethal gynecologic malignancy. Efforts at early detection and new therapeutic approaches to reduce mortality have been largely unsuccessful, because the origin and pathogenesis of epithelial ovarian cancer are poorly understood. Despite numerous studies that have carefully …
Acrylamide, classified in 1994 by the International Agency for Research on Cancer (IARC) as "probably carcinogenic" to humans, was discovered in 2002 in some heat-treated, carbohydrate-rich foods. The association between dietary acrylamide intake and epithelial ovarian cancer risk (EOC) has been previously studied in one case-control and three prospective cohort studies which obtained inconsistent results and could not further examine histologic subtypes other than serous EOC. The present study was carried out in the European Prospective Investigation into Cancer and Nutrition (EPIC) subcohort of women (n = 325,006). Multivariate Cox proportional hazards models were used to assess the association between questionnaire-based acrylamide intake and EOC risk. Acrylamide was energy-adjusted using the residual method and was evaluated both as a continuous variable (per 10 μg/d) and in quintiles; when subgroups by histologic EOC subtypes were analyzed, acrylamide intake was evaluated in quartiles. ...
Whilst previous studies have reported that higher BMI increases a womans risk of developing ovarian cancer, associations for the different histological subtypes have not been well defined. As the prevalence of obesity has increased dramatically, and classification of ovarian histology has improved in the last decade, we sought to examine the association in a pooled analysis of recent studies participating in the Ovarian Cancer Association Consortium. We evaluated the association between BMI (recent, maximum and in young adulthood) and ovarian cancer risk using original data from 15 case-control studies (13 548 cases and 17 913 controls). We combined study-specific adjusted odds ratios (ORs) using a random-effects model. We further examined the associations by histological subtype, menopausal status and post-menopausal hormone use. High BMI (all time-points) was associated with increased risk. This was most pronounced for borderline serous (recent BMI: pooled OR=1.24 per 5 kg/m2; 95% CI ...
In this study of consecutively recruited, richly annotated epithelial ovarian cancer patients from a single institution, we found that inherited interindividual differences in angiogenesis, and, to a lesser extent, inflammation, may influence survival time after adjustment for other prognostic factors. A unique aspect of our approach was the clinical, demographic, and treatment homogeneity of the patients studied which, when combined with high data completeness, allowed us to assess the role of inherited variants above and beyond known clinical factors. To our knowledge, this is the broadest investigation of the influence of host genetic pathways on ovarian cancer outcome to date.. Vascularization and expression of proangiogenic factors have been shown to correlate with prognosis of ovarian tumors (36). Bevacizumab, an antibody targeting VEGF, has recently shown significant promise in the treatment of ovarian cancer (9). We found that variation in VHL was associated with survival among all ...
Vol 7: Versican regulates metastasis of epithelial ovarian carcinoma cells and spheroids.. . Biblioteca virtual para leer y descargar libros, documentos, trabajos y tesis universitarias en PDF. Material universiario, documentación y tareas realizadas por universitarios en nuestra biblioteca. Para descargar gratis y para leer online.
Ovarian cancer starts in the ovaries and can rapidly spread to the rest of the reproductive system if it is not caught quickly. Epithelial ovarian tumors are the most common type of tumor found on the ovaries. Associated tumors are divided into three sub-groups: benign epithelial tumors, tumors of low malignant potential (LMP tumors), and malignant epithelial ovarian tumors. Malignant epithelial ovarian tumors are the most common form of ovarian cancer.. However, the symptoms of ovarian cancer are commonly overlooked or attributed to other less harmful health problems and are easily missed by both the patient and the doctor.. ...
Analysis of prognostic factors in stage I epithelial ovarian carcinoma: importance of degree of differentiation and deoxyribonucleic acid ploidy in predicting relapse
Prima BioMed Ltd (ASX: PRR) (NASDAQ: PBMD) (ISIN: US74154B2034) (Prima, the Company) today released interim immune monitoring data from its ongoing CAN-003 clinical trial of CVac to treat epithelial ovarian cancer patients in remission after first-line or second line therapy.
Background: Parity and use of oral contraceptive (OC) are associated with reduced risk of ovarian cancer. However, it is not clear whether these exposures have similar risk effects during different periods of life. In a large consortial analysis, we seek to evaluate the risk reductions associated with pregnancy and with OC use in different periods during the lifetime of a woman.. Methods: We combined data from 17 population-based case-control studies of ovarian cancer that are part of the Ovarian Cancer Association Consortium (OCAC). Odds ratios (ORs) and 95% confidence intervals (CI) for associations between age of pregnancies and duration of OC use were estimated in individual studies using logistic regression and combined using random effects meta-analysis. Analyses were adjusted for age, duration of OC use, number of pregnancies, and race (Caucasian, Black, Asian and other). Studies that matched on ethnicity were additionally adjusted for Hispanic ethnicity (yes/no). All tests were two-sided ...
Background: There is no standard treatment for patients with platinum-resistant or refractory epithelial ovarian cancer. Single agent chemotherapies have evidence of more efficacy and less toxicity than combination therapy. Most are very expensive, with appreciable toxicity and minimal survival. Since it is difficult to make comparison between outcomes, economic analysis of single-agent chemotherapy regimens and best supportive care may help to make decisions about an appropriate management for the affected patients. Objective: To evaluate the cost effectiveness of second-line chemotherapy compared with best supportive care for patients with platinum-resistant or refractory epithelial ovarian cancer. Materials and Methods: A Markov model was used to estimate the effectiveness and total costs associated with treatments. The hypothetical patient population comprised women aged 55 with platinum-resistant or refractory epithelial ovarian cancer. Four types of alternative treatment options were ...
The mortality rate for ovarian cancer has remained roughly unchanged for the past 40 years. Various targeted therapies for ovarian cancer are under investigati...
N 6-Methyladenosine (m6A) is the most abundant RNA modification in mammal mRNAs and increasing evidence suggests the key roles of m6A in human tumorigenesis. However, whether m6A, especially its reader YTHDF1, targets a gene involving in protein translation and thus affects overall protein production in cancer cells is largely unexplored. Here, using multi-omics analysis for ovarian cancer, we identified a novel mechanism involving EIF3C, a subunit of the protein translation initiation factor EIF3, as the direct target of the YTHDF1. YTHDF1 augments the translation of EIF3C in an m6A-dependent manner by binding to m6A-modified EIF3C mRNA and concomitantly promotes the overall translational output, thereby facilitating tumorigenesis and metastasis of ovarian cancer. YTHDF1 is frequently amplified in ovarian cancer and up-regulation of YTHDF1 is associated with the adverse prognosis of ovarian cancer patients. Furthermore, the protein but not the RNA abundance of EIF3C is increased in ovarian ...
Borderline epithelial ovarian tumors | Surgery. Gynecology: Treatment in Aachen, Germany ✈. Prices on BookingHealth.com - booking treatment online!
Surgical resection of borderline epithelial ovarian tumors (costs for program #130589) ✔ University Hospital Giessen UKGM ✔ Department of Gynecology and Obstetrics ✔ BookingHealth.com
Ligands to FGF receptor 2-IIIb induce proliferation, motility, protection from cell death and cytoskeletal rearrangements in epithelial ovarian cancer cell ...